Prasugrel in the Elderly

This publication has 12 references indexed in Scilit:

• Zotarolimus-Eluting Versus Bare-Metal Stents in Uncertain Drug-Eluting Stent Candidates
  JACC, 2015
• Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis
  BMJ, 2013
• Elderly Patients With Acute Coronary Syndromes Managed Without Revascularization
  Circulation, 2013
• Prasugrel 5 mg in the Very Elderly Attenuates Platelet Inhibition But Maintains Noninferiority to Prasugrel 10 mg in Nonelderly Patients
  JACC, 2013
• Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes
  Circulation: Cardiovascular Quality and Outcomes, 2012
• Stopping clinical trials early for futility: retrospective analysis of several randomised clinical studies
  British Journal of Cancer, 2012
• Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents
  Circulation, 2012
• Relationship Between Exposure to Prasugrel Active Metabolite and Clinical Outcomes in the TRITON‐TIMI 38 Substudy
  The Journal of Clinical Pharmacology, 2012
• Lower risk of stent thrombosis and restenosis with unrestricted use of ‘new-generation’ drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR)
  European Heart Journal, 2012
• Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
  New England Journal of Medicine, 2007